论文部分内容阅读
目的探讨来氟米特联合贝那普利治疗慢性肾小球肾炎的临床疗效。方法选取2012年3月—2014年3月阳煤集团总医院收治的慢性肾小球肾炎患者120例,采取随机抽样法将患者分为试验组与对照组,各60例。对照组患者予以常规治疗,试验组患者予以来氟米特联合贝那普利治疗。观察两组患者治疗前后24h尿蛋白定量,肝肾功能及不良反应情况。结果治疗前两组患者24h尿蛋白定量比较,差异无统计学意义(P>0.05),治疗后试验组患者24h尿蛋白定量低于对照组,差异有统计学意义(P<0.05)。试验组患者总有效率高于对照组,差异有统计学意义(P<0.05);试验组患者不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论来氟米特联合贝那普利治疗慢性肾小球肾炎的临床疗效显著,可有效降低患者24h尿蛋白定量,改善其肝肾功能,且不良反应少。
Objective To investigate the clinical efficacy of leflunomide and benazepril in the treatment of chronic glomerulonephritis. Methods A total of 120 patients with chronic glomerulonephritis admitted to Yangzhou Coal General Hospital from March 2012 to March 2014 were selected and randomly divided into experimental group and control group with 60 cases in each group. Patients in the control group were treated routinely, and patients in the test group were treated with leflunomide and benazepril. 24 hours before and after treatment, urinary protein, liver and kidney function and adverse reactions were observed. Results There was no significant difference in 24h urinary protein between the two groups before treatment (P> 0.05). After treatment, the urinary protein excretion of 24h group was lower than that of the control group (P <0.05). The total effective rate of the experimental group was higher than that of the control group, the difference was statistically significant (P <0.05). The incidence of adverse reactions in the experimental group was lower than that of the control group, the difference was statistically significant (P <0.05). Conclusion Leflunomide combined with benazepril in the treatment of chronic glomerulonephritis significant clinical effect, which can effectively reduce the 24h urinary protein in patients with quantitative, improve liver and kidney function, and less adverse reactions.